A Phase 3 Study of an Experimental Gene Therapy for Oculopharyngeal Muscular Dystrophy Will Take Place, Axovant Says

An experimental gene therapy program (called AXO-AAV-OPMD) being developed for the treatment of oculopharyngeal muscular dystrophy has been licensed with exclusive global rights to Axovant Sciences from Benitec Biopharma. There…

Continue Reading A Phase 3 Study of an Experimental Gene Therapy for Oculopharyngeal Muscular Dystrophy Will Take Place, Axovant Says
Exciting Development in Potential Oculopharyngeal Muscular Dystrophy Treatment
Source: Pixabay

Exciting Development in Potential Oculopharyngeal Muscular Dystrophy Treatment

A new gene therapy treatment may be on the horizon for Oculopharyngeal Muscular Dystrophy patients. Find out more below, or keep up with the original story at musculardystrophynews.com. Oculopharyngeal Muscular…

Continue Reading Exciting Development in Potential Oculopharyngeal Muscular Dystrophy Treatment
Close Menu